Magnesium Supplementation in Diabetic Nephropathy

• Status: Completed
• Trial end date: 2020-03-01
• Target enrollment: 0
• Participant gender: All

Summary

Higher prevalence of hypomagnesaemia in diabetic patients with nephropathy was compared to those without nephropathy. Serum magnesium levels were significantly inversely correlated with serum creatinine and U-A/C ratio, and positively correlated with glomerular filtration rate (GFR).

Hence, Magnesium supplementation using magnesium salts could be a good approach to improve the cardiovascular complications, insulin resistance index, lipid profile and kidney function in diabetic nephropathy patients.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Ain Shams University
• Treatments: Citric Acid; Hypoglycemic Agents; Magnesium citrate

Criteria

Inclusion Criteria:

1. Age ≥ 18 years.

2. Type I or II diabetic patientCKD stage 3 ( eGFR = 30 - 59 ml/min) or stage 4 ( eGFR 15-29 ml/min)

3. Proteinuria 30-300 mg/dl (microalbuminuria)

4. Low SMg levels (1.4-1.9 mg/dL; 0.58-0.78 mM) to normal (1.7-2.4 mg/dL; 0.7 -1.1 mmol/L; 1.4-2.0 mEq/L).

5. Life expectancy >12 months.

6. Women of child-bearing age should be using contraceptives as Hormonal contraceptive or Intra-uterine device.

Exclusion Criteria:

1. Kidney donor recipient.

2. Current treatment with Mg supplements.

3. Any condition impairing intestinal absorption of Mg (e.g: chronic pancreatitis, short bowel syndrome)

4. Active malignancy.

5. Pregnancy or breastfeeding.

6. Cardiac Arrythmias.

7. Allergy towards the Mg supplement.

8. Participation in other interventional trials.